Russell Investments Group Ltd. Raises Stock Position in Prestige Consumer Healthcare Inc. $PBH

Russell Investments Group Ltd. lifted its position in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 2.0% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 28,115 shares of the company’s stock after buying an additional 561 shares during the period. Russell Investments Group Ltd. owned approximately 0.06% of Prestige Consumer Healthcare worth $2,417,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of PBH. GAMMA Investing LLC boosted its stake in Prestige Consumer Healthcare by 35.9% in the 1st quarter. GAMMA Investing LLC now owns 1,879 shares of the company’s stock worth $162,000 after purchasing an additional 496 shares in the last quarter. KBC Group NV boosted its stake in Prestige Consumer Healthcare by 7.4% in the 1st quarter. KBC Group NV now owns 2,199 shares of the company’s stock worth $189,000 after purchasing an additional 151 shares in the last quarter. QRG Capital Management Inc. boosted its stake in Prestige Consumer Healthcare by 8.6% in the 1st quarter. QRG Capital Management Inc. now owns 5,971 shares of the company’s stock worth $513,000 after purchasing an additional 475 shares in the last quarter. BNP Paribas Financial Markets boosted its stake in Prestige Consumer Healthcare by 1,073.3% in the 4th quarter. BNP Paribas Financial Markets now owns 203,903 shares of the company’s stock worth $15,923,000 after purchasing an additional 186,524 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC boosted its stake in Prestige Consumer Healthcare by 14.1% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 8,315 shares of the company’s stock worth $649,000 after purchasing an additional 1,030 shares in the last quarter. Hedge funds and other institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare Trading Down 1.5%

Shares of PBH opened at $65.69 on Tuesday. Prestige Consumer Healthcare Inc. has a 52-week low of $62.95 and a 52-week high of $90.04. The company has a quick ratio of 2.99, a current ratio of 4.38 and a debt-to-equity ratio of 0.55. The firm’s fifty day moving average is $74.93 and its two-hundred day moving average is $81.03. The stock has a market cap of $3.23 billion, a PE ratio of 15.42, a price-to-earnings-growth ratio of 2.11 and a beta of 0.43.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings results on Thursday, August 7th. The company reported $0.95 earnings per share for the quarter, missing the consensus estimate of $1.01 by ($0.06). The firm had revenue of $249.53 million for the quarter, compared to analyst estimates of $260.71 million. Prestige Consumer Healthcare had a net margin of 19.02% and a return on equity of 12.69%. The company’s revenue was down 6.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.90 EPS. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.500-4.580 EPS. Research analysts forecast that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on PBH. Canaccord Genuity Group lowered their target price on shares of Prestige Consumer Healthcare from $105.00 to $100.00 and set a “buy” rating for the company in a research note on Friday, August 8th. Royal Bank Of Canada upgraded shares of Prestige Consumer Healthcare to a “hold” rating in a research note on Thursday, May 8th. Finally, Wall Street Zen lowered shares of Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a report on Saturday, August 9th. Three equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $93.33.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.